Blinatumomab

Drug Profile

Blinatumomab

Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Micromet Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; B cell prolymphocytic leukaemia; Acute lymphoblastic leukaemia; B cell lymphoma; T cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II Diffuse large B cell lymphoma
  • No development reported Non-Hodgkin's lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Acute lymphoblastic leukaemia (Combination therapy) in USA (IV) (NCT02877303)
  • 03 Oct 2016 Efficacy and adverse events data from the '205 phase I/II trial in Acute lymphoblastic leukaemia released by Amgen
  • 26 Sep 2016 Amgen plans a phase II/III trial for Non-Hodgkin lymphoma in USA, Canada, Belgium, Italy, Spain, United Kingdom and Australia (NCT02910063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top